The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Intersection · Compounds × ipamorelin

Compounds topics tagged ipamorelin

Topics in Compounds carrying the tag ipamorelin. Selective growth-hormone secretagogue.

20 topics

TopicParticipantsRepliesViewsActivity
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion
On the subject in the title: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of…
PPNKRVHBMM+47 53 6.9k 2h
Reading a rodent study on a secretagogue without over-extrapolating — the long version
Reading a rodent study on a secretagogue without over-extrapolating — the long version — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support…
CDDBANKBMA+59 66 30k 4h
CJC-1295 with and without DAC: what the modification does
On the subject in the title: CJC-1295 with and without DAC: what the modification does Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with SURMOUNT-OSA ( N Engl J Med ,…
MSNCDHEHNE+117 123 5.6k 22h
Tesamorelin has an approved indication — what that changes about the evidence
Tesamorelin has an approved indication — what that changes about the evidence — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-1 ( N Engl J…
FHPMOONBPW+23 27 3.4k 1d
Evidence quality in the secretagogue literature: an honest assessment
Evidence quality in the secretagogue literature: an honest assessment Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024) with STEP…
SSSVK 2 25k 9d
Secretagogues and glucose tolerance: the mechanistic concern
On the subject in the title: Secretagogues and glucose tolerance: the mechanistic concern Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
INRDMDOVFF+64 70 52k 17d
Why this subcategory is stricter about sourcing than most
Asking directly, because I could not find a straight answer: Why this subcategory is stricter about sourcing than most Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before posting; the…
DOCAEFRESC+48 52 617 21d
Secretagogues and glucose tolerance: the mechanistic concern — what changed since
Secretagogues and glucose tolerance: the mechanistic concern — what changed since Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021)…
TLDKAIEF+2 6 31k 2mo
Follow-up: Evidence quality in the secretagogue literature: an honest assessment
On the subject in the title: Evidence quality in the secretagogue literature: an honest assessment Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with LEADER ( N Engl J Med…
BSHRTMNCI+20 24 18k 4mo
IGF-1 as a surrogate endpoint and its limitations
IGF-1 as a surrogate endpoint and its limitations Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I do not…
OCSLTDCJN+5 9 35k 4mo
CJC-1295 with and without DAC: what the modification does — what changed since
CJC-1295 with and without DAC: what the modification does — what changed since Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024)…
SSCDSBGHNN 4 5.1k 7mo
Second pass at: Why this subcategory is stricter about sourcing than most
Second pass at: Why this subcategory is stricter about sourcing than most — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SURMOUNT-4 ( JAMA ,…
AWGHTVCDAS+120 129 61k 11mo
IGF-1 as a surrogate endpoint and its limitations — the long version
On the subject in the title: IGF-1 as a surrogate endpoint and its limitations — the long version Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of a claim I do…
NOMGCRKBGP+14 18 53k 12mo
Ipamorelin selectivity claims and where they came from
Ipamorelin selectivity claims and where they came from — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim I do not…
EKNRRBCWTI+51 56 8.8k 12mo
About the Secretagogues & GH axis category
GHRP class CJC-1295 ipamorelin Pinned Wiki Closed
Growth-hormone secretagogues and related compounds. Evidence quality here is markedly lower and we say so. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
KBNNHVSCN+6 10 1.1k 14mo
Ipamorelin selectivity claims and where they came from — a second dataset
Posting this under the heading it deserves: Ipamorelin selectivity claims and where they came from — a second dataset Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021)…
TIDCM 2 27k 14mo
Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset
The question in the title: Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset I will give what I have already checked below so nobody repeats it. I have seen LEADER ( N…
BRPDBJRMSG+60 64 25k 15mo
Coming back to: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021)…
BNGRKRZSHM+9 13 249 17mo
Revisiting: What a well-designed human trial of a secretagogue would look like
On the subject in the title: Revisiting: What a well-designed human trial of a secretagogue would look like Working notes rather than a conclusion. Session topic: SELECT ( N Engl J Med , 2023). Please read it…
HBSBOIDAS+69 74 25k 18mo
What a well-designed human trial of a secretagogue would look like
What a well-designed human trial of a secretagogue would look like I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited…
HORNR 2 7.2k 18mo